Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), with a market capitalization of approximately $5.9 billion, has been making waves in the pharmaceutical industry with its flagship drug Rezdiffra ...

Currently, the only approved treatment for MASH on the market is the thyroid hormone receptor β agonist resmetirom (Rezdiffra ...

“Rezdiffra demonstrated broad, sustained efficacy across multiple noninvasive parameters at two years of treatment. A high, statistically significant percentage of patients with CSPH or probable ...

Madrigal Pharmaceuticals announced positive results from the Phase 3 MAESTRO-NAFLD-1 trial of their drug Rezdiffra, focusing on patients with compensated metabolic dysfunction-associated ...

CONSHOHOCKEN, Pa., May 10, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction ...

Sagimet Biosciences' FASN inhibitors show promise in acne and metabolic disease. Read my analysis on SGMT stock and see why I ...

“Rezdiffra demonstrated broad, sustained efficacy across multiple noninvasive parameters at two years of treatment. A high, statistically significant percentage of patients with CSPH or probable CSPH ...

I’ve no history of nosebleeds, but over the past five weeks, I’ve had five. The first three times, the bleeding stopped after ...

"Rezdiffra demonstrated broad, sustained efficacy across multiple noninvasive parameters at two years of treatment. A high, statistically significant percentage of patients with CSPH or probable CSPH ...

Any thoughts on milk thistle supplements in fatty liver disease that was diagnosed by an ultrasound due to elevated AST and ...

Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) has demonstrated sustained efficacy in a late-stage trial of patients with liver disease. The company presented positive two-year results from the open ...

Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the 46th Annual Global Goldman Sachs Health Care Conference on Wednesday, June 11, 2025 at 10:40 A.M.